BR0109158A - Cepa alterada do vìrus de varìola bovina de ankara (mva) - Google Patents

Cepa alterada do vìrus de varìola bovina de ankara (mva)

Info

Publication number
BR0109158A
BR0109158A BR0109158-1A BR0109158A BR0109158A BR 0109158 A BR0109158 A BR 0109158A BR 0109158 A BR0109158 A BR 0109158A BR 0109158 A BR0109158 A BR 0109158A
Authority
BR
Brazil
Prior art keywords
mva
ankara
virus
pox virus
relates
Prior art date
Application number
BR0109158-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Anton Mayr
Original Assignee
Anton Mayr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anton Mayr filed Critical Anton Mayr
Publication of BR0109158A publication Critical patent/BR0109158A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0109158-1A 2000-03-14 2001-03-10 Cepa alterada do vìrus de varìola bovina de ankara (mva) BR0109158A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200000410 2000-03-14
PCT/EP2001/002703 WO2001068820A1 (en) 2000-03-14 2001-03-10 Altered strain of the modified vaccinia virus ankara (mva)

Publications (1)

Publication Number Publication Date
BR0109158A true BR0109158A (pt) 2003-04-22

Family

ID=8159327

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109158-1A BR0109158A (pt) 2000-03-14 2001-03-10 Cepa alterada do vìrus de varìola bovina de ankara (mva)

Country Status (25)

Country Link
US (1) US6682743B2 (enExample)
EP (1) EP1263936B1 (enExample)
JP (1) JP4759201B2 (enExample)
KR (1) KR100880765B1 (enExample)
CN (1) CN1291012C (enExample)
AT (1) ATE305030T1 (enExample)
AU (1) AU780696B2 (enExample)
BR (1) BR0109158A (enExample)
CA (1) CA2397675C (enExample)
CZ (1) CZ293690B6 (enExample)
DE (1) DE60113512T2 (enExample)
DK (1) DK1263936T3 (enExample)
EE (1) EE05633B1 (enExample)
ES (1) ES2249430T3 (enExample)
HK (1) HK1052725B (enExample)
HU (1) HU228691B1 (enExample)
IL (3) IL150736A0 (enExample)
MX (1) MXPA02008873A (enExample)
NO (1) NO20024246D0 (enExample)
NZ (1) NZ521270A (enExample)
PL (1) PL205922B1 (enExample)
RU (1) RU2280075C2 (enExample)
SI (1) SI1263936T1 (enExample)
UA (1) UA84388C2 (enExample)
WO (1) WO2001068820A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
DE20122302U1 (de) 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
EP1357127A1 (de) * 2002-04-10 2003-10-29 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
JP4801880B2 (ja) † 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ 新生仔予防接種用変異ワクシニアウイルスアンカラ
EP2253709B1 (en) * 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
UA85543C2 (ru) * 2002-09-05 2009-02-10 Бавариан Нордик А/С Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
DE602004009743T2 (de) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US7607323B1 (en) 2007-10-16 2009-10-27 Hall Charles F Curl resistant shirt collar and method of fabricating same
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2011063359A1 (en) * 2009-11-20 2011-05-26 Inviragen, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US20170021009A1 (en) * 2014-03-10 2017-01-26 Arizona Board Of Regents On Behalf Of Arizona State Heat Inactivated Poxvirus Improves Vaccination Results
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
NL2014148B1 (en) 2015-01-16 2017-01-05 Univ Erasmus Med Ct Rotterdam Combination vaccine for camelids.
WO2016144564A2 (en) * 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP7406377B2 (ja) 2017-05-15 2023-12-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定なウイルス含有組成物
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
WO2022232375A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
US20250361513A1 (en) * 2022-05-04 2025-11-27 University Of Maryland, College Park Rna vectors with hairpin-like inserts
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2076735C1 (ru) * 1994-03-23 1997-04-10 ГНЦВБ "Вектор" Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
JP4460762B2 (ja) * 1997-10-15 2010-05-12 旭化成ファーマ株式会社 トロンボモジュリン水溶液注射剤の貯蔵・流通時の品質保持方法
JP3736622B2 (ja) * 2001-06-15 2006-01-18 セイコーエプソン株式会社 ライン駆動回路、電気光学装置及び表示装置

Also Published As

Publication number Publication date
IL150736A (en) 2008-06-05
HUP0300120A3 (en) 2010-01-28
PL357378A1 (en) 2004-07-26
AU5826901A (en) 2001-09-24
IL150736A0 (en) 2003-02-12
RU2280075C2 (ru) 2006-07-20
HK1052725A1 (en) 2003-09-26
NO20024246L (no) 2002-09-05
NZ521270A (en) 2003-06-30
EP1263936A1 (en) 2002-12-11
CN1418248A (zh) 2003-05-14
IL188667A (en) 2011-09-27
JP2003526362A (ja) 2003-09-09
CA2397675A1 (en) 2001-09-20
HU228691B1 (en) 2013-05-28
NO20024246D0 (no) 2002-09-05
US6682743B2 (en) 2004-01-27
EE200200507A (et) 2004-02-16
RU2002124622A (ru) 2004-03-27
WO2001068820A1 (en) 2001-09-20
MXPA02008873A (es) 2003-02-10
ATE305030T1 (de) 2005-10-15
PL205922B1 (pl) 2010-06-30
EE05633B1 (et) 2013-02-15
CA2397675C (en) 2012-11-13
SI1263936T1 (sl) 2006-06-30
UA84388C2 (ru) 2008-10-27
HK1052725B (zh) 2007-03-23
US20030013190A1 (en) 2003-01-16
AU780696B2 (en) 2005-04-14
DE60113512T2 (de) 2006-06-22
ES2249430T3 (es) 2006-04-01
KR20030032928A (ko) 2003-04-26
CN1291012C (zh) 2006-12-20
IL188667A0 (en) 2008-04-13
JP4759201B2 (ja) 2011-08-31
KR100880765B1 (ko) 2009-02-02
EP1263936B1 (en) 2005-09-21
CZ293690B6 (cs) 2004-07-14
DK1263936T3 (da) 2006-02-13
DE60113512D1 (de) 2006-02-02
HUP0300120A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
BR0109158A (pt) Cepa alterada do vìrus de varìola bovina de ankara (mva)
BR112023000827A2 (pt) Métodos, vacina, métodos para fabricar uma vacina, para tratar um indivíduo e para fabricar um tratamento para um indivíduo, composição farmacêutica, peptídeo imunogênico, sequência de ácido nucleico, sistema e produto de programa de computador
BRPI0414443A (pt) imunógenos consensuais/ancestrais
BR0114305A (pt) Micropartìculas para liberação de ácidos nucléicos heterólogos
BR0210225A (pt) Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante
BR0309809A (pt) indução de toleráncia imunológica especìfica quanto ao antìgeno
BR0210216A (pt) Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante
BR9915026A (pt) Móleculas de ácido nucléico codificando uma enzima ramificadora de bactérias do gênero neisseria bem como métodos para a produção de alfa-1,4 glicanos ramificados para alfa-1,6
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
DE60024112D1 (de) Influenzavirus-impfstoffzusammensetzung
BRPI0408085A (pt) composição e método para o tratamento e prevenção de infecções entéricas bacterianas
BR112023019301A2 (pt) Formulações de vacina de coronavírus
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
BR112023012205A2 (pt) Construto de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método de preparação do construto e vacina
DK1066376T3 (da) Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
ATE284613T1 (de) Polynukleotid-impfstoff-formulierungen
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
BRPI0515428A (pt) terapia por injeção ao tumor de células dendrìticas (dcti)
BR112013004582A2 (pt) método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
BR0209145A (pt) Vacina contra varìola
PE20120116A1 (es) Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta hemolitica (bhs)
BR0207447A (pt) Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina
BR0116704A (pt) Antìgenos de streptococcus pyogenes e fragmentos de dna correspondentes

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: BAVARIAN NORDIC A/S (DK)

B25G Requested change of headquarter approved

Owner name: BAVARIAN NORDIC A/S (DK)

Free format text: ALTERADA A SEDE DO TITULAR CONFORME REQUERIDA ATRAVES DA PETICAO NO 055511/RJ DE 28/09/2004.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 8O 13, 24, 25, 10, 18, DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.